Inside informationEnglish
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 30/06/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 115187_20250630